AbCellera Biologics Inc. (ABCL) Stock

About AbCellera Biologics Inc.

AbCellera Biologics Inc. is led by CEO Carl Hansen, employs 596 people, headquartered in CA, publicly traded since 2020.

AbCellera Biologics Inc. (ABCL) stock trades at $11.82 with a market capitalization of $3.83B. The stock is valued at a negative price-to-earnings (P/E) ratio of -21.26, reflecting a net loss over the last twelve months, price-to-book of 3.91, price-to-sales of 52.98. Over the past 52 weeks the stock has ranged between $2.75 and $15.02, and currently trades 21.3% below its 52-week high.

On profitability, AbCellera Biologics Inc. generates a return on equity (ROE) of -17.49% (negative, reflecting a net loss), return on capital employed of -16.78%, an operating margin of -2.68%, a net profit margin of -248.83%.

AbCellera Biologics Inc. by the numbers, 2018–2025

Between 2018 and 2025 AbCellera Biologics Inc. reported revenue of $9.0M rising to $75.0M, a change of +733.3% across 8 years. Compounded, revenue has grown -20.3% a year over five years, -46.3% over three, 158.6% over the last twelve months. Net profit was $-146.0M in 2025.

Operating margin went from -8.5% in 2018 to -289.0% in 2025, a fall of 280.5 percentage points. The most recent net margin is -248.83%. On a trailing twelve-month basis to Jun '26, revenue is $66.0M and net profit $-164.0M.

Borrowings rose from $3.0M to $143.0M, cash from operations was $-131.0M in the latest year, positive in 5 of the last 8.

Return on equity has averaged -3.1% over five years, and was -15.1% in the most recent year.

The share price itself has compounded at -32.0% a year over five years, -4.8% over three, 140.3% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

AbCellera Biologics Inc. (ABCL) — frequently asked questions